IP Verse

Quantification Of Misfolded Tnfr2:Fc - EP2975050

The patent EP2975050 was granted to Sandoz on May 29, 2019. The application was originally filed on Jul 18, 2014 under application number EP14177696A. The patent is currently recorded with a legal status of "Revoked".

EP2975050

SANDOZ
Application Number
EP14177696A
Filing Date
Jul 18, 2014
Status
Revoked
Apr 2, 2022
Grant Date
May 29, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

EUROPEAN OPPOSITIONSFeb 28, 2020KILBURN & STRODEADMISSIBLE

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS6048728
DESCRIPTIONUS7294481
DESCRIPTIONWO2011134920
DESCRIPTIONWO2011134921
OPPOSITIONCN102382190
OPPOSITIONUS7294481
OPPOSITIONWO2012176158
OPPOSITIONWO2013025079
OPPOSITIONWO2014102814
SEARCHUS2014072560
SEARCHUS7294481
SEARCHWO2014144911

Non-Patent Literature (NPL) Citations (8) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- MUKAI ET AL., "Solution of the Structure of the TNF-TNFR2 Complex", SCI SIGNAL, (201011), vol. 3, page 148-
DESCRIPTION- MUKAI ET AL., "Solution of the Structure of the TNF-TNFR2 Complex.", SCI SIGNAL, (2010), vol. 3, no. 148, page RA83-
OPPOSITION- Anonymous, "BLA 761042 GP2015, a proposed biosimilar to Enbrel (etanercept) Sandoz", FDA Briefing Document Arthritis Advisory Committee Meeting, (20160713), pages 1 - 68, FDA Briefing Document Arthritis Advisory Committee Meeting, URL: https://www.fda.gov/media/99309/download, (20200610), XP055703610-
OPPOSITION- Li-Juan Huang, Et Al, "Complete mapping of disulfide linkages for etanercept products by multi-enzyme digestion coupled with LC-MS/MS using multi-fragmentations including CID and ETD", Journal of Food and Drug Analysis, (20190101), vol. 27, no. 2, pages 531 - 541, XP055703629
OPPOSITION- Víctor Pérez Medina Martínez et al, "Comparability of a Three-Dimensional Structure in Biopharmaceuticals Using Spectroscopic Methods", Journal of Analytical Methods in Chemistry, Hindawi Publishing Corporation, (20140101), vol. 18, no. 2, doi:10.1038/359752a0, ISSN 2090-8865, pages 248 - 11, XP055153777
OPPOSITION- William C. Lamanna et al, "The structure-function relationship of disulfide bonds in etanercept", Scientific Reports, (20171201), vol. 7, no. 1, doi:10.1038/s41598-017-04320-5, XP055703616
OPPOSITION- Pei Lung Tsai, Et Al, "Mass spectrometry-based strategies for protein disulfide bond identification", Reviews in Analytical Chemistry, (20130101), vol. 32, no. 4, pages 257 - 268, XP055703639
SEARCH- VÍCTOR PÉREZ MEDINA MARTÍNEZ ET AL, "Comparability of a Three-Dimensional Structure in Biopharmaceuticals Using Spectroscopic Methods", JOURNAL OF ANALYTICAL METHODS IN CHEMISTRY, (20140101), vol. 18, no. 2, doi:10.1038/359752a0, ISSN 2090-8865, pages 248 - 11, XP055153777 [A] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents